In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease.

Voyager will receive $65 million up front. The biotech is eligible for another $245 million in preclinical milestones and option payments for up to four programs through Phase I, at which point AbbVie may opt to license each program. Voyager is eligible for another $1.2 billion in development, regulatory and commercial milestones, plus royalties...